Although serum prostate specific antigen (PSA) testing is often used to monitor disease recurrence after definitive therapy for prostate cancer [65], Krause et al. identified a positive correlation between 11C-choline PET detection rate and serum PSA levels [66]. This evidence concerns the gene KLK3 and prostate carcinoma.